Brahms AG   Report issue

For profit Phase 3
Founded: Henningsdorf Germany (1994)
Status: Acquired by Thermo Fisher Scientific (2009)

Organization Overview

First Clinical Trial
2009
NCT00832039
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Brahms AG

Active Ingredients

Drugs in Phase 3 Trials (2)

procalcitonin (2 trials)

selenium (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sepsis (Phase 3)

Shock, Septic (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2